Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 5,325 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Continuous Dose Clear all

Conditions: Metastatic Cancer
Interventions: LY3007113; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Santa Monica, California • San Antonio, Texas

Conditions: Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Azacitidine Injection, sodium phenylbutyrate; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Neuromuscular Blockade
Interventions: Rocuronium Bromide, Cisatracurium Besylate; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 85 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Basal Cell Carcinoma
Interventions: LDE225; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 22
States / cities: Fayetteville, Arkansas • Los Angeles, California • Stanford, California + 17 more

Conditions: Hypertension, Pulmonary
Interventions: Riociguat (Adempas, BAY63-2521); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 7
States / cities: La Jolla, California • Sacramento, California • Iowa City, Iowa + 4 more

Conditions: Human Health, Reactive Carbonyl Species, Polyphenols
Interventions: Soymilk, green tea, or blueberry, Control group; Dietary Supplement
Lead sponsor: North Carolina Agriculture & Technical State University; Other
Eligibility: 25 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Kannapolis, North Carolina

Conditions: Solid Tumors
Interventions: ME-344; Drug
Lead sponsor: MEI Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee

Conditions: Breast Neoplasms
Interventions: Sunitinib + Capecitabine, Capecitabine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 442 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 79
States / cities: Downey, California • Fresno, California • Montebello, California + 56 more

Conditions: Uterine Cancer
Interventions: Paclitaxel and carboplatin combination; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Coronavirus Infection
Interventions: Selinexor, Placebo; Drug · Other
Lead sponsor: Karyopharm Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 20
States / cities: Los Angeles, California • Oakland, California • Sacramento, California + 15 more

Conditions: Esophageal Cancer, Gastric Cancer
Interventions: G17DT Immunogen, cisplatin, fluorouracil; Biological · Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Rheumatoid Arthritis (RA)
Interventions: Non-invasive ultrasound stimulation of the spleen - Treatment Setting 1, Non-invasive ultrasound stimulation of the spleen - Treatment Setting 2, Sham ultrasound stimulation (control), Conventional Synthetic DMARD; Device · Drug
Lead sponsor: SecondWave Systems Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Glendale, Arizona • Covina, California • Temecula, California + 2 more

Conditions: Burns, Hemofiltration, Kidney Failure, Acute, Shock, Septic
Interventions: An FDA approved continuous renal replacement device, Control Group; Device · Other
Lead sponsor: American Burn Association; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 9
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia • Tampa, Florida + 6 more

Conditions: Hypertension
Interventions: nitroprusside, placebo infusion; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 1 Day to 17 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 8
States / cities: Little Rock, Arkansas • Stanford, California • Louisville, Kentucky + 4 more

Conditions: Cardiac Surgery, Older Adults, Depression, Anxiety
Interventions: Behavioral activation, Medication optimzation, Care as usual; Behavioral · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 60 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Metastatic Solid Tumor, Lymphoma, Myeloproliferative Neoplasms (MPN)
Interventions: PU-H71; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Aging
Interventions: Motor Practice of a Standing Serial Reaction Time Task; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 95 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Hemophilia A
Interventions: Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM); Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: Up to 6 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 17
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 14 more

Conditions: Interference With Routine Analytical Tests, Stability of in Vitro Diagnostic Reagents, Illicit Drug Use
Interventions: Device storage condition, Interferent application; Device
Lead sponsor: Intelligent Bio Solutions Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Marlton, New Jersey

Conditions: Plasma Cell Myeloma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Filgrastim-sndz, Melphalan Hydrochloride; Procedure · Biological · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Limb-Girdle Muscular Dystrophy
Interventions: Deflazacort; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 8
States / cities: Atlanta, Georgia • Iowa City, Iowa • Kansas City, Kansas + 5 more

Conditions: Smoking Cessation, Harm Reduction
Interventions: Varenicline, e-cigarette; Drug · Other
Lead sponsor: Rose Research Center, LLC; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Charlotte, North Carolina • Raleigh, North Carolina

Conditions: Hypertrophy, Left Ventricular
Interventions: carvedilol MR, atenolol, lisinopril; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 78
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 65 more

Conditions: Glioblastoma, Glioblastoma With Primitive Neuronal Component, Gliosarcoma, Malignant Glioma, Oligodendroglial Component Present
Interventions: Plerixafor, Temozolomide, Whole-Brain Radiotherapy (WBRT), Radiation Therapy; Drug · Radiation
Lead sponsor: Lawrence D Recht; Other
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Palo Alto, California

Search by objective public record fields.

A Study of LY3007113 in Participants With Advanced Cancer

Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment

Determination of TOF Test Threshold for Obtaining Reliable Pedicle Screw Stimulation Test During Lumbar Spine Surgery

A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor

Scavenging of Reactive Carbonyl Species by Dietary Flavonoids in Humans

Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors

A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer

A Phase II Study of Paclitaxel and Carboplatin in Patients With an Elevated-Risk Cancer of the Uterus

Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection

Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer

At-home Ultrasound Localized Therapy for Rheumatoid Arthritis Study [At-home ULTRA Study]

Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)

Sodium Nitroprusside for Blood Pressure Reduction in the ICU (SNP2)

Behavioral Activation and Medication Optimization In Older Adults Undergoing Cardiac Procedures

The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies

Does Overpractice Improve Motor Learning?

Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients

Interference and Stability Evaluation of the Intelligent Fingerprinting Drug Screening System

Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation

A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)

Combination of E-cigarettes and Varenicline for Tobacco Harm Reduction

The CLEVER Study - Coreg And Left Ventricular Mass Regression

Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma